生基医药宣告与GeneMedicine达到溶瘤病毒产品研制和生产合作

▎药明康德/报导

我国上海，韩国首尔，2019年11月29日——药明康德子公司生基医药宣告与韩国基因医治生物公司GeneMedicine达到战略协作协议，为GeneMedicine的要害研制项目供给掩盖溶瘤病毒产品开发、出产和FDA临床试验申报所需的服务。这是生基医药继本年8月宣告与锦斯生物一起开辟溶瘤病毒CDMO服务渠道后，签署的第一个世界客户服务项目，标志着生基医药能够为全球客户供给契合世界标准的溶瘤病毒产品研制和出产服务，助力客户加快立异疗法提前进入市场，谋福全球病患。

GeneMedicine公司现在有多个项目处于临床开发阶段，包含实体肿瘤、转移性肝癌和肺癌、胰腺癌等范畴。经过此次协作，生基医药-锦斯生物溶瘤病毒CDMO服务渠道将为GeneMedicine供给从病毒库制作、病毒库判定到工艺开发和cGMP出产服务，助力客户加快要害药物管线的研制和临床试验进程。

GeneMedicine首席执行官Chae-Ok Yun博士表明：“生基医药具有掩盖全基因医治范畴产品类型的一体化研制和出产服务渠道，契合世界标准的质量体系和专业的办理团队，将协助咱们加快推进更多药物研制项目提前进入临床。”

“咱们很侥幸成为GeneMedicine的协作伙伴，推进其溶瘤病毒项目研制出产进程。”生基医药总经理姚树元博士表明，“生基医药具有一体化的基因医治产品研制出产服务渠道，掩盖了从产品开发转化到商业化出产的全产业链。咱们致力于赋能全球客户加快基因医治产品的研制出产进程，让更多的立异疗法提前上市，谋福病患。”

关于GeneMedicine

GeneMedicine是一家具有溶瘤腺病毒技能渠道的基因医治生物公司，具有丰厚而谨慎的溶瘤病毒研制经历。公司经过不同的基因医治产品管线研制，进步患者生活品质。GeneMedicine许诺实行社会职责，经过开发突破性的基因医治技能和道德办理实践，旨在成为全球医疗保健范畴的领导者。

关于生基医药

无锡生基医药科技有限公司（“生基医药”）于2017年9月成立于江苏省无锡惠山经济开发区，是上海药明康德新药开发有限公司（“药明康德”）的全资子公司，首要从事细胞医治用产品、基因载体的研制、出产以及其它相关服务事务。生基医药已建成上海研制基地、无锡研制基地和无锡GMP出产基地；无锡研制和出产基地坐落无锡惠山经济开发区生命科技产业园，总面积13000多平方米。

生基医药将充沛的利用药明康德在细胞基因医治方面堆集十多年的技能和服务经历，在国内打造一个掩盖基因细胞疗法产品出产全过程，集研制、出产、产品报批咨询等为一体的一站式服务渠道。生基医药的服务项目将包含基因载体质粒GMP出产、基因载体研制和GMP出产、以及细胞疗法产品研制和GMP出产等。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业供给全方位、一体化的新药研制和出产服务。经过赋能全球制药、生物科技和医疗器械公司，药明康德致力于推进新药研制进程，为患者带来突破性的医治计划。本着以研讨为首任，以客户为中心的主旨，药明康德经过超高的性价比和高效的研制服务，助力客户提高研制功率，服务范围包含化学药研制和出产、细胞及基因疗法研制出产、医疗器械测验等范畴。现在，药明康德的赋能渠道正承载着来自全球30多个国家的3700多家协作伙伴的研制立异项目，致力于将更多新药、好药带给全球病患，提前完成“让天下没有难做的药，难治的病”的愿景。更多信息，请拜访公司网站：elerate the development of gene therapy and bring more advanced treatment to global patients.”

about GeneMedicine

GeneMedicine Co., Ltd., is a gene therapeutic specializing bioventure with oncolytic adenovirus platform technologies. These state-of-the-art platforms are a culmination of 25 years of extensive and rigorous research development. We firmly believe that our pipelines can improve the quality-of-life and symptoms of cancer patients suffering from intractable diseases through innovative and specialized therapeutic solutions. GeneMedicine Co., Ltd. promises to fulfill its social responsibility through the development of groundbreaking gene therapeutic and ethical management practice, aiming to become a global healthcare leader.

about WuXi ATU Co., Ltd.

WuXi ATU Co., Ltd. (hereinafter referred to as “WuXi ATU”) was founded in September 2017 at the Huishan Economic Development Zone, Wuxi City. It is a wholly owned subsidiary of WuXi AppTec (Shanghai) Co., Ltd. (hereinafter referred to as "WuXi AppTec"). It engages primarily in cell therapy products and gene vector research and development, production and other related services. WuXi ATU includes Shanghai R&D base, Wuxi R&D base and Wuxi GMP production base. Wuxi R&D base and production base is located at the Life Science and Technology Industrial Park of Huishan Economic Development Zone, with facilities occupying more than 140,000 square feet.

WuXi ATU will make full use of WuXi AppTec's service experience in the area of cell gene therapy for more than ten years, and will build a one-stop service platform in China, covering the whole process of production of gene cell therapy products and integrating research and development, production and consultation. WuXi ATU's services will include GMP production of gene vector plasmids, research and development of gene vectors and GMP production, as well as research and development of cell therapy products and GMP production.

about WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated." Please visit: http://.

版权阐明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或组织未经授权以任何方式转载至其他渠道。转载授权请在「药明康德」微信大众号回复“转载”，获取转载须知。